Initial analysis of the WES‐derived mutational landscape indicated an aberrant gene spectrum comparable with de novo DLBCL, with frequent mutation (>20%) of TP53, KMT2D, MYD88, GNA13, and PIM1, highlighting common pathogenic pathways (Figure 3A). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.